Spectrum Pharmaceuticals Highlights Five Abstracts on ROLONTIS™ (eflapegrastim) & Poziotinib at the San Antonio Breast Canc...
December 05 2016 - 7:00AM
Business Wire
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology
company with fully integrated commercial and drug development
operations with a primary focus in Hematology and Oncology, today
announced key presentations of clinical and scientific data related
to its products at the San Antonio Breast Cancer Symposium (SABCS),
being held in San Antonio, Texas, from December 6-10,
2016.
For more information about the SABCS meeting and for a complete
list of abstracts, please refer to the conference website
at http://www.abstracts2view.com/sabcs/.
The following are key ROLONTISTM (eflapegrastim) related
abstracts being presented at the SABCS meeting:
Abstract # Type
Title First Author
Date/TimeLocation: Hall 1 OT1-01-11
Poster
Randomized phase 3 study of a novel,
long-acting G-CSF (eflapegrastim) versus pegfilgrastim in the
management of chemotherapy-induced neutropenia in early-stage
breast cancer patients receiving docetaxel and cyclophosphamide
(TC) (ADVANCE study)
Schwartzberg Wednesday, Dec 75:00 PM
P5-11-09 Poster
Sustained efficacy of eflapegrastim in
breast cancer patients in a phase 2, open-label, dose-ranging
study
Vacirca Friday, Dec 9
5:00 PM
P5-11-07 Poster
Pharmacokinetics of eflapegrastim in a
phase 2 open-label dose-ranging study in breast cancer patients
receiving TC regimen
Vacirca Friday, Dec 9
5:00 PM
P5-11-08 Poster
Immunogenicity of eflapegrastim in a Phase
2 Open-Label Dose-Ranging Study of eflapegrastim in Breast Cancer
Patients Receiving TC Regimen
Vacirca Friday, Dec 9
5:00 PM
The following key poziotinib related abstract will be presented
at the SABCS meeting:
Abstract # Type
Title First Author
Date/TimeLocation: Hall 1 OT1-02-10
Poster
A phase 2 study of poziotinib in patients
with HER2-positive metastatic breast cancer (MBC) who have received
prior HER2 regimens for MBC
Lathrop Wednesday, Dec 75:00 PM
About Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals is a leading biotechnology company
focused on acquiring, developing, and commercializing drug
products, with a primary focus in Hematology and Oncology. Spectrum
currently markets six hematology/oncology drugs, and has an
advanced stage pipeline that has the potential to transform
the Company. Spectrum's strong track record for in-licensing and
acquiring differentiated drugs, and expertise in clinical
development have generated a robust, diversified, and growing
pipeline of product candidates in advanced-stage Phase 2 and Phase
3 studies. More information on Spectrum is available
at www.sppirx.com.
Forward-looking statement — This press release may contain
forward-looking statements regarding future events and the future
performance of Spectrum Pharmaceuticals that involve risks and
uncertainties that could cause actual results to differ materially.
These statements are based on management's current beliefs and
expectations. These statements include, but are not limited to,
statements that relate to Spectrum’s business and its future,
including certain company milestones, Spectrum's ability to
identify, acquire, develop and commercialize a broad and diverse
pipeline of late-stage clinical and commercial products, the timing
and results of FDA decisions, and any statements that relate to the
intent, belief, plans or expectations of Spectrum or its
management, or that are not a statement of historical fact. Risks
that could cause actual results to differ include the possibility
that Spectrum’s existing and new drug candidates may not prove safe
or effective, the possibility that our existing and new
applications to the FDA and other regulatory agencies may not
receive approval in a timely manner or at all, the possibility that
our existing and new drug candidates, if approved, may not be more
effective, safer or more cost efficient than competing drugs, the
possibility that our efforts to acquire or in-license and develop
additional drug candidates may fail, our dependence on third
parties for clinical trials, manufacturing, distribution and
quality control and other risks that are described in further
detail in the Company's reports filed with the Securities and
Exchange Commission. The Company does not plan to update any such
forward-looking statements and expressly disclaims any duty to
update the information contained in this press release except as
required by law.
SPECTRUM PHARMACEUTICALS, INC.® is a registered trademark of
Spectrum Pharmaceuticals, Inc and its affiliate. REDEFINING CANCER
CARE™, ROLONTISTM and the Spectrum Pharmaceuticals logos are
trademarks owned by Spectrum Pharmaceuticals, Inc. Any other
trademarks are the property of their respective owners.
© 2016 Spectrum Pharmaceuticals, Inc. All Rights Reserved
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161205005150/en/
Spectrum PharmaceuticalsShiv KapoorVice President, Strategic
Planning & Investor
Relations702-835-6300InvestorRelations@sppirx.com
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From Apr 2024 to May 2024
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From May 2023 to May 2024